Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
E C Keystone, M C Genovese, L Klareskog, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-796. The safety data reported in Table 4 of this manuscript actually include data beyond week 24. Because the trial design allowed for patients in three of the four treatment groups to enter early escape, and all remaining patients in the placebo plus MTX group crossed over to golimumab at week 24, the numbers of patients reported in the treatment groups in Table 4 differ from the numbers of patients randomized to each treatment group. A footnote should have been added to this table noting: “Data beyond week 24 were included in this analysis” for clarification.